Download PDF
Exp Clin Endocrinol Diabetes 2006; 114(6): 275-294
DOI: 10.1055/s-2006-924260
Article

J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Genetics of Diabetic Retinopathy

K. Uhlmann1 , P. Kovacs1 , Y. Boettcher1 , H.-P. Hammes2 , R. Paschke1
  • 1Department of Endocrinology and Diabetes, University of Leipzig, Leipzig, Germany
  • 25th Medical Department, University of Mannheim, Mannheim
Further Information

Publication History

Received: July 25, 2005 First decision: January 27, 2006

Accepted: February 24, 2006

Publication Date:
26 July 2006 (online)

Also available at
    Permissions and Reprints

Abstract

Familial aggregation as well as racial and ethnic differences in incidence suggest that genetic components play a role in the development of diabetic retinopathy (DR), several approaches have been used to identify genes contributing to the development of retinopathy. We searched the literature database using the keywords [diabetes], [gene], for publications dealing with retinopathy. 88 original publications reporting data on genetics of retinopathy were found. For the purpose of this review, a simple scoring system was applied, that results in a score for each considered gene to indicate its potential relevance in genetic control of retinopathy. Based on published studies, the most intriguing genes for further genetic studies are aldose receptor, advanced glycation end products receptor, vascular endothelial growth factor, intercellular adhesion molecule 1, β3-adrenergic receptor gene, hemochromatosis, and α2β1 integrin. Pathways involving these gene products may represent a fruitful area for further studies aimed at investigating the genetics and pathophysiology of DR. Meta-analyses of candidate gene studies may provide further useful insights into their role. In addition, our paper addresses several issues challenging genetic studies of retinopathy such as replication of associations, patient ascertainment schemes, or accurately defined phenotypes.

Key words

Type 2 diabetes - polymorphism - quantitative trait - review - association

References

  • 1 Adamis A P, Miller J W, Bernal M T, D'Amico D J, Folkman J, Yeo T K, Yeo K T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy.  Am J Ophthalmol. 1994;  118 445-450
    CrossrefPubMedGoogle Scholar
  • 2 Aiello L P, Avery R L, Arrigg P G, Keyt B A, Jampel H D, Shah S T, Pasquale L R, Thieme H, Iwamoto M A, Park J E. et al . Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.  N Engl J Med. 1994;  331 1480-1487
    CrossrefPubMedGoogle Scholar
  • 3 Aksoy H, Akcay F, Kurtul N, Baykal O, Avci B. Serum 1, 25 dihydroxy vitamin D (1, 25(OH)2D3), 25 hydroxy vitamin D (25(OH)D), and parathormone levels in diabetic retinopathy.  Clin Biochem. 2000;  33 47-51
    CrossrefPubMedGoogle Scholar
  • 4 Alcolado J C, Baroni M G, Li S R, Galton D J. Genetic variation around the collagen IV 1a gene locus and proliferative retinopathy in type 2 diabetes mellitus.  Hum Hered. 1993;  43 126-130
    PubMedGoogle Scholar
  • 5 Anonymous . Diabetic retinopathy study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Prepared by the Diabetic Retinopathy.  Invest Ophthalmol Vis Sci. 1981;  21 1-226
    PubMedGoogle Scholar
  • 6 Anonymous . Diabetes mellitus. Report of a WHO Study Group.  World Health Organ Tech Rep Ser. 1985;  727 1-113
    PubMedGoogle Scholar
  • 7 Anonymous . Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. The TIMAD Study Group.  Arch Ophthalmol. 1990;  108 1577-1583
    PubMedGoogle Scholar
  • 8 Anonymous . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group.  N Engl J Med. 1993;  329 977-986
    Google Scholar
  • 9 Anonymous . Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study.  Diabetologia. 1994;  37 278-285
    CrossrefPubMedGoogle Scholar
  • 10 Anonymous . Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group.  Diabetes. 1997;  46 1829-1839
    PubMedGoogle Scholar
  • 11 Anonymous . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.  Lancet. 1998;  352 837-853
    CrossrefPubMedGoogle Scholar
  • 12 Anonymous . Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.  Lancet. 2000;  355 253-259
    CrossrefPubMedGoogle Scholar
  • 13 Anonymous . The International HapMap Project.  Nature. 2003;  426 789-796
    CrossrefPubMedGoogle Scholar
  • 14 Arauz-Pacheco C, Ramirez L C, Pruneda L, Sanborn G E, Rosenstock J, Raskin P. The effect of the aldose reductase inhibitor, ponalrestat, on the progression of diabetic retinopathy.  J Diabetes Complications. 1992;  6 131-137
    CrossrefPubMedGoogle Scholar
  • 15 Araz M, Yilmaz N, Gungor K, Okan V, Kepekci Y, Sukru A A. Angiotensin-converting enzyme gene polymorphism and microvascular complications in Turkish type 2 diabetic patients.  Diabetes Res Clin Pract. 2001;  54 95-104
    CrossrefPubMedGoogle Scholar
  • 16 Aso Y, Inukai T, Tayama K, Takemura Y. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes.  Acta Diabetol. 2000;  37 87-92
    CrossrefPubMedGoogle Scholar
  • 17 Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, Inoue I, Katayama S. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes.  Diabetes. 2002;  51 1635-1639
    PubMedGoogle Scholar
  • 18 Awata T, Neda T, Iizuka H, Kurihara S, Ohkubo T, Takata N, Osaki M, Watanabe M, Nakashima Y, Sawa T, Inukai K, Inoue I, Shibuya M, Mori K, Yoneya S, Katayama S. Endothelial nitric oxide synthase gene is associated with diabetic macular edema in type 2 diabetes.  Diabetes Care. 2004;  27 2184-2190
    PubMedGoogle Scholar
  • 19 Beranek M, Kankova K, Benes P, Izakovicova-Holla L, Znojil V, Hajek D, Vlkova E, Vacha J. Polymorphism R25P in the gene encoding transforming growth factor-beta (TGF-beta1) is a newly identified risk factor for proliferative diabetic retinopathy.  Am J Med Genet. 2002;  109 278-283
    CrossrefPubMedGoogle Scholar
  • 20 Beranek M, Kankova K, Kolar P, Znojil V. Polymorphisms in the von Willebrand factor gene are not associated with proliferative retinopathy in non-insulin-dependent diabetes mellitus.  Ophthalmic Res. 2002 b;  34 327-330
    CrossrefPubMedGoogle Scholar
  • 21 Beranek M, Kankova K, Tschoplova S, Kolar P, Vacha J. Three novel polymorphisms in the promoter region of the TIMP‐3 gene are not associated with proliferative diabetic retinopathy in type 2 diabetes mellitus.  Curr Eye Res. 2003;  27 91-93
    CrossrefPubMedGoogle Scholar
  • 22 Boehm B O, Schilling S, Rosinger S, Lang G E, Lang G K, Kientsch-Engel R, Stahl P. Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema.  Diabetologia. 2004;  47 1376-1379
    PubMedGoogle Scholar
  • 23 Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.  N Engl J Med. 1988;  318 1315-1321
    CrossrefPubMedGoogle Scholar
  • 24 Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.  Science. 1986;  232 1629-1632
    CrossrefPubMedGoogle Scholar
  • 25 Carlson C S, Eberle M A, Kruglyak L, Nickerson D A. Mapping complex disease loci in whole-genome association studies.  Nature. 2004;  429 446-452
    CrossrefPubMedGoogle Scholar
  • 26 Carr M C, Brunzell J D. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk.  J Clin Endocrinol Metab. 2004;  89 2601-2607
    CrossrefPubMedGoogle Scholar
  • 27 Chandra T, Lakshmi C N, Padma T, Vidyavathi M, Satapathy M. Haptoglobin phenotypes in diabetes mellitus and diabetic retinopathy.  Hum Hered. 1991;  41 347-350
    PubMedGoogle Scholar
  • 28 Chew E Y, Klein M L, Ferris III F L, Remaley N A, Murphy R P, Chantry K, Hoogwerf B J, Miller D. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22.  Arch Ophthalmol. 1996;  114 1079-1084
    PubMedGoogle Scholar
  • 29 Chistiakov D A, Demurov L M, Kondrat'ev I, Milen'kaia T M, Mamaeva G G, Balabolkin M I, Nosikov V V. [Polymorphism of the angiotensin I-converting enzyme gene in diabetic retinopathy patients and type 2 diabetes mellitus patients with myocardial infarction].  Genetika. 1998;  34 1699-1703
    PubMedGoogle Scholar
  • 30 Dahlman I, Eaves I A, Kosoy R, Morrison V A, Heward J, Gough S C, Allahabadia A, Franklyn J A, Tuomilehto J, Tuomilehto-Wolf E, Cucca F, Guja C, Ionescu-Tirgoviste C, Stevens H, Carr P, Nutland S, McKinney P, Shield J P, Wang W, Cordell H J, Walker N, Todd J A, Concannon P. Parameters for reliable results in genetic association studies in common disease.  Nat Genet. 2002;  30 149-150
    PubMedGoogle Scholar
  • 31 Dawson D W, Volpert O V, Gillis P, Crawford S E, Xu H, Benedict W, Bouck N P. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.  Science. 1999;  285 245-248
    CrossrefPubMedGoogle Scholar
  • 32 Deinum J, Derkx F H, Danser A H, Schalekamp M A. Identification and quantification of renin and prorenin in the bovine eye.  Endocrinology. 1990;  126 1673-1682
    PubMedGoogle Scholar
  • 33 Docherty A J, O'Connell J, Crabbe T, Angal S, Murphy G. The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases.  Trends Biotechnol. 1992;  10 200-207
    CrossrefPubMedGoogle Scholar
  • 34 Doi Y, Yoshizumi H, Yoshinari M, Iino K, Yamamoto M, Ichikawa K, Iwase M, Fujishima M. Association between a polymorphism in the angiotensin-converting enzyme gene and microvascular complications in Japanese patients with NIDDM.  Diabetologia. 1996;  39 97-102
    PubMedGoogle Scholar
  • 35 Dudley C R, Keavney B, Stratton I M, Turner R C, Ratcliffe P J. U.K. Prospective Diabetes Study. XV: Relationship of renin-angiotensin system gene polymorphisms with microalbuminuria in NIDDM.  Kidney Int. 1995;  48 1907-1911
    PubMedGoogle Scholar
  • 36 Duh E, Aiello L P. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox.  Diabetes. 1999;  48 1899-1906
    CrossrefPubMedGoogle Scholar
  • 37 Engerman R L, Kern T S. Experimental galactosemia produces diabetic-like retinopathy.  Diabetes. 1984;  33 97-100
    PubMedGoogle Scholar
  • 38 Erdos E G, Skidgel R A. The angiotensin I-converting enzyme.  Lab Invest. 1987;  56 345-348
    PubMedGoogle Scholar
  • 39 Fernandes R, Suzuki K, Kumagai A K. Inner blood-retinal barrier GLUT1 in long-term diabetic rats: an immunogold electron microscopic study.  Invest Ophthalmol Vis Sci. 2003;  44 3150-3154
    CrossrefPubMedGoogle Scholar
  • 40 Fernandez-Real J M, Molina A, Broch M, Ricart W, Gutierrez C, Casamitjana R, Vendrell J, Soler J, Gomez-Saez J M. Tumor necrosis factor system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy.  Diabetes. 1999;  48 1108-1112
    PubMedGoogle Scholar
  • 41 Fernandez-Real J M, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome.  Endocr Rev. 2003;  24 278-301
    CrossrefPubMedGoogle Scholar
  • 42 Fernandez-Real J M, Vendrell J, Ricart W, Broch M, Gutierrez C, Casamitjana R, Oriola J, Richart C. Polymorphism of the tumor necrosis factor-alpha receptor 2 gene is associated with obesity, leptin levels, and insulin resistance in young subjects and diet-treated type 2 diabetic patients.  Diabetes Care. 2000;  23 831-837
    PubMedGoogle Scholar
  • 43 Ferrara N. Vascular endothelial growth factor. The trigger for neovascularization in the eye.  Lab Invest. 1995;  72 615-618
    PubMedGoogle Scholar
  • 44 Florez J C, Hirschhorn J, Altshuler D. The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits.  Annu Rev Genomics Hum Genet. 2003;  4 257-291
    CrossrefPubMedGoogle Scholar
  • 45 Frank R N. Diabetic retinopathy.  N Engl J Med. 2004;  350 48-58
    CrossrefPubMedGoogle Scholar
  • 46 Fujisawa T, Ikegami H, Kawaguchi Y, Hamada Y, Ueda H, Shintani M, Fukuda M, Ogihara T. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy.  Diabetologia. 1998;  41 47-53
    CrossrefPubMedGoogle Scholar
  • 47 Fujisawa T, Ikegami H, Kawaguchi Y, Yamato E, Nakagawa Y, Shen G Q, Fukuda M, Ogihara T. Length rather than a specific allele of dinucleotide repeat in the 5′ upstream region of the aldose reductase gene is associated with diabetic retinopathy.  Diabet Med. 1999;  16 1044-1047
    CrossrefPubMedGoogle Scholar
  • 48 Fujisawa T, Ikegami H, Shen G Q, Yamato E, Takekawa K, Nakagawa Y, Hamada Y, Ueda H, Rakugi H, Higaki J. Angiotensin I-converting enzyme gene polymorphism is associated with myocardial infarction, but not with retinopathy or nephropathy, in NIDDM.  Diabetes Care. 1995;  18 983-985
    PubMedGoogle Scholar
  • 49 Fujiwara Y, Tagami S, Kawakami Y. Circulating thrombomodulin and hematological alterations in type 2 diabetic patients with retinopathy.  J Atheroscler Thromb. 1998;  5 21-28
    PubMedGoogle Scholar
  • 50 Fukuda M. Clinical arrangement of classification of diabetic retinopathy.  Tohoku J Exp Med. 1983;  141 331-335
    PubMedGoogle Scholar
  • 51 Globocnik-Petrovic M, Hawlina M, Peterlin B, Petrovic D. Insertion/deletion plasminogen activator inhibitor 1 and insertion/deletion angiotensin-converting enzyme gene polymorphisms in diabetic retinopathy in type 2 diabetes.  Ophthalmologica. 2003;  217 219-224
    CrossrefPubMedGoogle Scholar
  • 52 Grainger D J, Kemp P R, Liu A C, Lawn R M, Metcalfe J C. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice.  Nature. 1994;  370 460-462
    CrossrefPubMedGoogle Scholar
  • 53 Grainger D J, Kirschenlohr H L, Metcalfe J C, Weissberg P L, Wade D P, Lawn R M. Proliferation of human smooth muscle cells promoted by lipoprotein(a).  Science. 1993;  260 1655-1658
    CrossrefPubMedGoogle Scholar
  • 54 Grzeszczak W, Moczulski D K, Zychma M, Zukowska-Szczechowska E, Trautsolt W, Szydlowska I. Role of GLUT1 gene in susceptibility to diabetic nephropathy in type 2 diabetes.  Kidney Int. 2001;  59 631-636
    CrossrefPubMedGoogle Scholar
  • 55 Guillausseau P J, Massin P, Charles M A, Allaguy H, Guvenli Z, Virally M, Tielmans D, Assayag M, Warnet A, Lubetzki J. Glycaemic control and development of retinopathy in type 2 diabetes mellitus: a longitudinal study.  Diabet Med. 1998;  15 151-155
    CrossrefPubMedGoogle Scholar
  • 56 Guillausseau P J, Tielmans D, Virally-Monod M, Assayag M. Diabetes: from phenotypes to genotypes.  Diabetes Metab. 1997;  23 Suppl 2 14-21
    PubMedGoogle Scholar
  • 57 Gutierrez C, Vendrell J, Pastor R, Broch M, Aguilar C, Llor C, Simon I, Richart C. GLUT1 gene polymorphism in non-insulin-dependent diabetes mellitus: genetic susceptibility relationship with cardiovascular risk factors and microangiopathic complications in a Mediterranean population.  Diabetes Res Clin Pract. 1998;  41 113-120
    CrossrefPubMedGoogle Scholar
  • 58 Gutierrez C, Vendrell J, Pastor R, Llor C, Aguilar C, Broch M, Richart C. Angiotensin I-converting enzyme and angiotensinogen gene polymorphisms in non-insulin-dependent diabetes mellitus. Lack of relationship with diabetic nephropathy and retinopathy in a Caucasian Mediterranean population.  Metabolism. 1997;  46 976-980
    CrossrefPubMedGoogle Scholar
  • 59 Ha S K, Park H C, Park H S, Kang B S, Lee T H, Hwang H J, Kim S J, Kim D H, Kang S W, Choi K H, Lee H Y, Han D S. ACE gene polymorphism and progression of diabetic nephropathy in Korean type 2 diabetic patients: effect of ACE gene DD on the progression of diabetic nephropathy.  Am J Kidney Dis. 2003;  41 943-949
    CrossrefPubMedGoogle Scholar
  • 60 Hamada Y, Kitoh R, Raskin P. Association of erythrocyte aldose reductase activity with diabetic complications in type 1 diabetes mellitus.  Diabet Med. 1993;  10 33-38
    PubMedGoogle Scholar
  • 61 Hammes H P, Brownlee M, Lin J, Schleicher E, Bretzel R G. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations.  Diabetologia. 1999;  42 603-607
    CrossrefPubMedGoogle Scholar
  • 62 Hammes H P, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy.  Nat Med. 2003;  9 294-299
    CrossrefPubMedGoogle Scholar
  • 63 Hammes H P, Lin J, Renner O, Shani M, Lundqvist A, Betsholtz C, Brownlee M, Deutsch U. Pericytes and the pathogenesis of diabetic retinopathy.  Diabetes. 2002;  51 3107-3112
    CrossrefPubMedGoogle Scholar
  • 64 Hawrami K, Hitman G A, Rema M, Snehalatha C, Viswanathan M, Ramachandran A, Mohan V. An association in non-insulin-dependent diabetes mellitus subjects between susceptibility to retinopathy and tumor necrosis factor polymorphism.  Hum Immunol. 1996;  46 49-54
    CrossrefPubMedGoogle Scholar
  • 65 Herrmann S M, Ringel J, Wang J G, Staessen J A, Brand E. Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study.  Diabetes. 2002;  51 2653-2657
    PubMedGoogle Scholar
  • 66 Hohman T C, Nishimura C, Robison Jr W G. Aldose reductase and polyol in cultured pericytes of human retinal capillaries.  Exp Eye Res. 1989;  48 55-60
    CrossrefPubMedGoogle Scholar
  • 67 Howard A A, Arnsten J H, Gourevitch M N. Effect of alcohol consumption on diabetes mellitus: a systematic review.  Ann Intern Med. 2004;  140 211-219
    PubMedGoogle Scholar
  • 68 Hudson B I, Stickland M H, Futers T S, Grant P J. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy.  Diabetes. 2001;  50 1505-1511
    CrossrefPubMedGoogle Scholar
  • 69 Hudson B I, Stickland M H, Grant P J. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups.  Diabetes. 1998;  47 1155-1157
    PubMedGoogle Scholar
  • 70 Ichikawa F, Yamada K, Ishiyama-Shigemoto S, Yuan X, Nonaka K. Association of an (A - C)n dinucleotide repeat polymorphic marker at the 5′-region of the aldose reductase gene with retinopathy but not with nephropathy or neuropathy in Japanese patients with Type 2 diabetes mellitus.  Diabet Med. 1999;  16 744-748
    CrossrefPubMedGoogle Scholar
  • 71 Ikegishi Y, Tawata M, Aida K, Onaya T. Z‐4 allele upstream of the aldose reductase gene is associated with proliferative retinopathy in Japanese patients with NIDDM, and elevated luciferase gene transcription in vitro.  Life Sci. 1999;  65 2061-2070
    CrossrefPubMedGoogle Scholar
  • 72 Imperatore G, Hanson R L, Pettitt D J, Kobes S, Bennett P H, Knowler W C. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group.  Diabetes. 1998;  47 821-830
    PubMedGoogle Scholar
  • 73 Ishii H, Jirousek M R, Koya D, Takagi C, Xia P, Clermont A, Bursell S E, Kern T S, Ballas L M, Heath W F, Stramm L E, Feener E P, King G L. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor.  Science. 1996;  272 728-731
    CrossrefPubMedGoogle Scholar
  • 74 Isotani H, Nakamura Y, Kameoka K, Tanaka K, Furukawa K, Kitaoka H, Ohsawa N. Pulmonary diffusing capacity, serum angiotensin-converting enzyme activity and the angiotensin-converting enzyme gene in Japanese non-insulin-dependent diabetes mellitus patients.  Diabetes Res Clin Pract. 1999;  43 173-177
    CrossrefPubMedGoogle Scholar
  • 75 JiXiong X, BiLin X, MingGong Y, ShuQin L. - 429T/C and - 374T/A polymorphisms of RAGE gene promoter are not associated with diabetic retinopathy in Chinese patients with type 2 diabetes.  Diabetes Care. 2003;  26 2696-2697
    PubMedGoogle Scholar
  • 76 Joussen A M, Murata T, Tsujikawa A, Kirchhof B, Bursell S E, Adamis A P. Leukocyte-mediated endothelial cell injury and death in the diabetic retina.  Am J Pathol. 2001;  158 147-152
    PubMedGoogle Scholar
  • 77 Joussen A M, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Dohmen S, Adamis A P. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression.  FASEB J. 2002;  16 438-440
    CrossrefPubMedGoogle Scholar
  • 78 Kamiuchi K, Hasegawa G, Obayashi H, Kitamura A, Ishii M, Yano M, Kanatsuna T, Yoshikawa T, Nakamura N. Intercellular adhesion molecule-1 (ICAM‐1) polymorphism is associated with diabetic retinopathy in Type 2 diabetes mellitus.  Diabet Med. 2002;  19 371-376
    CrossrefPubMedGoogle Scholar
  • 79 Kankova K, Beranek M, Hajek D, Vlkova E. Polymorphisms 1704G/T, 2184A/G, and 2245G/A in the rage gene are not associated with diabetic retinopathy in NIDDM: pilot study.  Retina. 2002;  22 119-121
    PubMedGoogle Scholar
  • 80 Kankova K, Muzik J, Karaskova J, Beranek M, Hajek D, Znojil V, Vlkova E, Vacha J. Duration of non-Insulin-dependent diabetes mellitus and the TNF-beta NcoI genotype as predictive factors in proliferative diabetic retinopathy.  Ophthalmologica. 2001;  215 294-298
    CrossrefPubMedGoogle Scholar
  • 81 Kern T S, Engerman R L. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin.  Diabetes. 2001;  50 1636-1642
    PubMedGoogle Scholar
  • 82 Klein R, Klein B E, Moss S E. The Wisconsin epidemiological study of diabetic retinopathy: a review.  Diabetes Metab Rev. 1989;  5 559-570
    PubMedGoogle Scholar
  • 83 Ko B C, Lam K S, Wat N M, Chung S S. An (A - C)n dinucleotide repeat polymorphic marker at the 5′ end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients.  Diabetes. 1995;  44 727-732
    PubMedGoogle Scholar
  • 84 Kohner E M, Porta M. Protocols for screening and treatment of diabetic retinopathy in Europe.  Eur J Ophthalmol. 1991;  1 45-54
    PubMedGoogle Scholar
  • 85 Korstanje R, Paigen B. From QTL to gene: the harvest begins.  Nat Genet. 2002;  31 235-236
    PubMedGoogle Scholar
  • 86 Koulu M, Movafagh S, Tuohimaa J, Jaakkola U, Kallio J, Pesonen U, Geng Y, Karvonen M K, Vainio-Jylha E, Pollonen M, Kaipio-Salmi K, Seppala H, Lee E W, Higgins R D, Zukowska Z. Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization.  Ann Med. 2004;  36 232-240
    CrossrefPubMedGoogle Scholar
  • 87 Kumaramanickavel G, Ramprasad V L, Sripriya S, Upadyay N K, Paul P G, Sharma T. Association of Gly82Ser polymorphism in the RAGE gene with diabetic retinopathy in type II diabetic Asian Indian patients.  J Diabetes Complications. 2002;  16 391-394
    CrossrefPubMedGoogle Scholar
  • 88 Kumaramanickavel G, Sripriya S, Ramprasad V L, Upadyay N K, Paul P G, Sharma T. Z‐2 aldose reductase allele and diabetic retinopathy in India.  Ophthalmic Genet. 2003;  24 41-48
    CrossrefPubMedGoogle Scholar
  • 89 Kumaramanickavel G, Sripriya S, Vellanki R N, Upadyay N K, Badrinath S S, Arokiasamy T, Sukumar B, Vidhya A, Joseph B, Sharma T, Gopal L. Tumor necrosis factor allelic polymorphism with diabetic retinopathy in India.  Diabetes Res Clin Pract. 2001;  54 89-94
    CrossrefPubMedGoogle Scholar
  • 90 Kumaramanickavel G, Sripriya S, Vellanki R N, Upadyay N K, Badrinath S S, Rajendran V, Sukumar B, Ramprasad V L, Sharma T. Inducible nitric oxide synthase gene and diabetic retinopathy in Asian Indian patients.  Clin Genet. 2002 b;  61 344-348
    CrossrefPubMedGoogle Scholar
  • 91 Kunisaki M, Bursell S E, Clermont A C, Ishii H, Ballas L M, Jirousek M R, Umeda F, Nawata H, King G L. Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerol-protein kinase C pathway.  Am J Physiol. 1995;  269 E239-E246
    PubMedGoogle Scholar
  • 92 Larkins R G, Dunlop M E. The link between hyperglycaemia and diabetic nephropathy.  Diabetologia. 1992;  35 499-504
    CrossrefPubMedGoogle Scholar
  • 93 Le Noble F A, Hekking J W, Van Straaten H W, Slaaf D W, Struyker Boudier H A. Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo.  Eur J Pharmacol. 1991;  195 305-306
    CrossrefPubMedGoogle Scholar
  • 94 Lee S C, Wang Y, Ko G T, Critchley J A, Ng M C, Tong P C, Cockram C S, Chan J C. Association of retinopathy with a microsatellite at 5′ end of the aldose reductase gene in Chinese patients with late-onset Type 2 diabetes.  Ophthalmic Genet. 2001;  22 63-67
    CrossrefPubMedGoogle Scholar
  • 95 Leske M C, Wu S Y, Hyman L, Li X, Hennis A, Connell A M, Schachat A P. Diabetic retinopathy in a black population: the Barbados Eye Study.  Ophthalmology. 1999;  106 1893-1899
    CrossrefPubMedGoogle Scholar
  • 96 Leslie R D, Pyke D A. Diabetic retinopathy in identical twins.  Diabetes. 1982;  31 19-21
    PubMedGoogle Scholar
  • 97 Li Q, Xie P, Huang J, Gu Y, Zeng W, Song H. Polymorphisms and functions of the aldose reductase gene 5′ regulatory region in Chinese patients with type 2 diabetes mellitus.  Chin Med J (Engl). 2002;  115 209-213
    PubMedGoogle Scholar
  • 98 Liao L, Lei M, Chen H, Han X, Fan C. [Studies on ACE gene insertion/deletion polymorphism, serum ACE activity, and diabetic retinopathy in type II diabetic patients].  Hunan Yi Ke Da Xue Xue Bao. 1999;  24 33-36
    PubMedGoogle Scholar
  • 99 Liu L, Xiang K. RAGE Gly82Ser polymorphism in diabetic microangiopathy.  Diabetes Care. 1999;  22 646
    PubMedGoogle Scholar
  • 100 Liu Z H, Guan T J, Chen Z H, Li L S. Glucose transporter (GLUT1) allele (XbaI-) associated with nephropathy in non-insulin-dependent diabetes mellitus.  Kidney Int. 1999;  55 1843-1848
    CrossrefPubMedGoogle Scholar
  • 101 Mackness B, Durrington P N, Abuashia B, Boulton A J, Mackness M I. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy.  Clin Sci (Lond). 2000;  98 355-363
    PubMedGoogle Scholar
  • 102 Maeda M, Yamamoto I, Fukuda M, Nishida M, Fujitsu J, Nonen S, Igarashi T, Motomura T, Inaba M, Fujio Y, Azuma J. MTHFR gene polymorphism as a risk factor for diabetic retinopathy in type 2 diabetic patients without serum creatinine elevation.  Diabetes Care. 2003;  26 547-548
    PubMedGoogle Scholar
  • 103 Mansfield M W, Stickland M H, Carter A M, Grant P J. Polymorphisms of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes, and in patients with diabetic retinopathy.  Thromb Haemost. 1994;  71 731-736
    PubMedGoogle Scholar
  • 104 Martidis A, Duker J S, Greenberg P B, Rogers A H, Puliafito C A, Reichel E, Baumal C. Intravitreal triamcinolone for refractory diabetic macular edema.  Ophthalmology. 2002;  109 920-927
    CrossrefPubMedGoogle Scholar
  • 105 Matsubara Y, Murata M, Maruyama T, Handa M, Yamagata N, Watanabe G, Saruta T, Ikeda Y. Association between diabetic retinopathy and genetic variations in alpha2beta1 integrin, a platelet receptor for collagen.  Blood. 2000;  95 1560-1564
    PubMedGoogle Scholar
  • 106 Matsumoto A, Iwashima Y, Abiko A, Morikawa A, Sekiguchi M, Eto M, Makino I. Detection of the association between a deletion polymorphism in the gene encoding angiotensin I-converting enzyme and advanced diabetic retinopathy.  Diabetes Res Clin Pract. 2000;  50 195-202
    PubMedGoogle Scholar
  • 107 Miles L A, Fless G M, Scanu A M, Baynham P, Sebald M T, Skocir P, Curtiss L K, Levin E G, Hoover-Plow J L, Plow E F. Interaction of Lp(a) with plasminogen binding sites on cells.  Thromb Haemost. 1995;  73 458-465
    PubMedGoogle Scholar
  • 108 Miloserdova O V, Slominskii P A, Mauianov I V, Markov D S, Balabolkin M I, Limborskaia S A. [Association between insertion-deletion polymorphism of the angiotensin-converting enzyme gene and development of angiopathies in patients with non-insulin dependent diabetes mellitus from the Chuvash Republic].  Genetika. 2001;  37 112-116
    PubMedGoogle Scholar
  • 109 Mizutani M, Kern T S, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy.  J Clin Invest. 1996;  97 2883-2890
    CrossrefPubMedGoogle Scholar
  • 110 Moravski C J, Kelly D J, Cooper M E, Gilbert R E, Bertram J F, Shahinfar S, Skinner S L, Wilkinson-Berka J L. Retinal neovascularization is prevented by blockade of the renin-angiotensin system.  Hypertension. 2000;  36 1099-1104
    PubMedGoogle Scholar
  • 111 Morris B J, Markus A, Glenn C L, Adams D J, Colagiuri S, Wang L. Association of a functional inducible nitric oxide synthase promoter variant with complications in type 2 diabetes.  J Mol Med. 2002;  80 96-104
    CrossrefPubMedGoogle Scholar
  • 112 Moss S E, Klein R, Klein B E. Ten-year incidence of visual loss in a diabetic population.  Ophthalmology. 1994;  101 1061-1070
    PubMedGoogle Scholar
  • 113 Moss S E, Klein R, Klein B E. The association of alcohol consumption with the incidence and progression of diabetic retinopathy.  Ophthalmology. 1994 b;  101 1962-1968
    PubMedGoogle Scholar
  • 114 Moss S E, Klein R, Klein B E. Cigarette smoking and ten-year progression of diabetic retinopathy.  Ophthalmology. 1996;  103 1438-1442
    PubMedGoogle Scholar
  • 115 Moss S E, Klein R, Klein B E. The 14-year incidence of visual loss in a diabetic population.  Ophthalmology. 1998;  105 998-1003
    CrossrefPubMedGoogle Scholar
  • 116 Murata M, Maruyama T, Suzuki Y, Saruta T, Ikeda Y. Paraoxonase 1 Gln/Arg polymorphism is associated with the risk of microangiopathy in Type 2 diabetes mellitus.  Diabet Med. 2004;  21 837-844
    CrossrefPubMedGoogle Scholar
  • 117 Nagi D K, Mansfield M W, Stickland M H, Grant P J. Angiotensin converting enzyme (ACE) insertion/deletion (I/D) polymorphism, and diabetic retinopathy in subjects with IDDM and NIDDM.  Diabet Med. 1995;  12 997-1001
    PubMedGoogle Scholar
  • 118 Nagi D K, McCormack L J, Mohamed-Ali V, Yudkin J S, Knowler W C, Grant P J. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI‐1 gene, and PAI‐1 activity in Pima Indians with type 2 diabetes.  Diabetes Care. 1997;  20 1304-1309
    PubMedGoogle Scholar
  • 119 Nebert D W, Petersen D D, Puga A. Human AH locus polymorphism and cancer: inducibility of CYP1A1 and other genes by combustion products and dioxin.  Pharmacogenetics. 1991;  1 68-78
    PubMedGoogle Scholar
  • 120 Nedospasov S A, Udalova I A, Kuprash D V, Turetskaya R L. DNA sequence polymorphism at the human tumor necrosis factor (TNF) locus. Numerous TNF/lymphotoxin alleles tagged by two closely linked microsatellites in the upstream region of the lymphotoxin (TNF-beta) gene.  J Immunol. 1991;  147 1053-1059
    PubMedGoogle Scholar
  • 121 Nishimura C, Saito T, Ito T, Omori Y, Tanimoto T. High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients.  Diabetologia. 1994;  37 328-330
    PubMedGoogle Scholar
  • 122 Niskanen L, Voutilainen-Kaunisto R, Terasvirta M, Karvonen M K, Valve R, Pesonen U, Laakso M, Uusitupa M I, Koulu M. Leucine 7 to proline 7 polymorphism in the neuropeptide y gene is associated with retinopathy in type 2 diabetes.  Exp Clin Endocrinol Diabetes. 2000;  108 235-236
    Article in Thieme ConnectPubMedGoogle Scholar
  • 123 Olmos P, Futers S, Acosta A M, Siegel S, Maiz A, Schiaffino R, Morales P, Diaz R, Arriagada P, Claro J C, Vega R, Vollrath V, Velasco S, Emmerich M. (AC)23 [Z‐2] polymorphism of the aldose reductase gene and fast progression of retinopathy in Chilean type 2 diabetics.  Diabetes Res Clin Pract. 2000;  47 169-176
    CrossrefPubMedGoogle Scholar
  • 124 Park H K, Ahn C W, Lee G T, Kim S J, Song Y D, Lim S K, Kim K R, Huh K B, Lee H C. (AC)(n) polymorphism of aldose reductase gene and diabetic microvascular complications in type 2 diabetes mellitus.  Diabetes Res Clin Pract. 2002;  55 151-157
    CrossrefPubMedGoogle Scholar
  • 125 Peterlin B, Globocnik P M, Makuc J, Hawlina M, Petrovic D. A hemochromatosis-causing mutation C282Y is a risk factor for proliferative diabetic retinopathy in Caucasians with type 2 diabetes.  J Hum Genet. 2003;  48 646-649
    CrossrefPubMedGoogle Scholar
  • 126 Petrovic M G, Hawlina M, Peterlin B, Petrovic D. BglII gene polymorphism of the alpha2beta1 integrin gene is a risk factor for diabetic retinopathy in Caucasians with type 2 diabetes.  J Hum Genet. 2003;  48 457-460
    CrossrefPubMedGoogle Scholar
  • 127 Petrovic M G, Steblovnik K, Peterlin B, Petrovic D. The - 429 T/C and - 374 T/A Gene Polymorphisms of the Receptor of Advanced Glycation End Products Gene are not Risk Factors for Diabetic Retinopathy in Caucasians with Type 2 Diabetes.  Klin Monatsbl Augenheilkd. 2003 b;  220 873-876
    Article in Thieme ConnectPubMedGoogle Scholar
  • 128 Pickup J C, Mattock M B, Chusney G D, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X.  Diabetologia. 1997;  40 1286-1292
    CrossrefPubMedGoogle Scholar
  • 129 Pucci L, Lucchesi D, Fotino C, Grupillo M, Miccoli R, Penno G, Del Prato S. [Integrin Beta 3 PlA1/PlA2 polimorphism does not contribute to complications in both type 1 and type 2 diabetes].  G Ital Nefrol. 2003;  20 461-469
    PubMedGoogle Scholar
  • 130 Quiroz-Mercado H, Suarez-Licona A, Fromow-Guerra J, Lopez-Carasa G, Cardenas-Hernandez R, Ruiz-Morales J A, Portal-Celhay C, Granados J. Human lymphocyte antigen DR7 protects against proliferative retinopathy with type II diabetes mellitus.  Arch Med Res. 2002;  33 123-127
    CrossrefPubMedGoogle Scholar
  • 131 Ray D, Mishra M, Ralph S, Read I, Davies R, Brenchley P. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes.  Diabetes. 2004;  53 861-864
    CrossrefPubMedGoogle Scholar
  • 132 Redondo M J, Fain P R, Eisenbarth G S. Genetics of type 1A diabetes.  Recent Prog Horm Res. 2001;  56 69-89
    CrossrefPubMedGoogle Scholar
  • 133 Reiner A P, Agardh E, Teramura G, Gaur P, Gaur L K, Agardh C D. Diabetes duration may modify the association between genetic variation in the glycoprotein Ia subunit of the platelet collagen receptor and risk of severe diabetic retinopathy: a working hypothesis.  Thromb Haemost. 2003;  89 142-148
    PubMedGoogle Scholar
  • 134 Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.  J Clin Invest. 1990;  86 1343-1346
    CrossrefPubMedGoogle Scholar
  • 135 Ringel J, Engeli S, Distler A, Sharma A M. Pro12Ala missense mutation of the peroxisome proliferator activated receptor gamma and diabetes mellitus.  Biochem Biophys Res Commun. 1999;  254 450-453
    CrossrefPubMedGoogle Scholar
  • 136 Ringel J, Kreutz R, Distler A, Sharma A M. The Trp64Arg polymorphism of the beta3-adrenergic receptor gene is associated with hypertension in men with type 2 diabetes mellitus.  Am J Hypertens. 2000;  13 1027-1031
    CrossrefPubMedGoogle Scholar
  • 137 Risch N, Merikangas K. The future of genetic studies of complex human diseases.  Science. 1996;  273 1516-1517
    CrossrefPubMedGoogle Scholar
  • 138 Robison Jr W G, Kador P F, Kinoshita J H. Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor.  Science. 1983;  221 1177-1179
    PubMedGoogle Scholar
  • 139 Sakane N, Yoshida T, Yoshioka K, Nakamura Y, Umekawa T, Kogure A, Takakura Y, Kondo M. Beta 3-adrenoreceptor gene polymorphism: a newly identified risk factor for proliferative retinopathy in NIDDM patients.  Diabetes. 1997;  46 1633-1636
    PubMedGoogle Scholar
  • 140 Santos K G, Tschiedel B, Schneider J, Souto K, Roisenberg I. Diabetic retinopathy in Euro-Brazilian type 2 diabetic patients: relationship with polymorphisms in the aldose reductase, the plasminogen activator inhibitor-1 and the methylenetetrahydrofolate reductase genes.  Diabetes Res Clin Pract. 2003;  61 133-136
    CrossrefPubMedGoogle Scholar
  • 141 Schmidt A M, Yan S D, Wautier J L, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis.  Circ Res. 1999;  84 489-497
    CrossrefPubMedGoogle Scholar
  • 142 Simorre-Pinatel V, Guerrin M, Chollet P, Penary M, Clamens S, Malecaze F, Plouet J. Vasculotropin-VEGF stimulates retinal capillary endothelial cells through an autocrine pathway.  Invest Ophthalmol Vis Sci. 1994;  35 3393-3400
    PubMedGoogle Scholar
  • 143 Sliwa-Strojek K, Grzeszczak W, Romaniuk W, Dorecka M, Kozera A. [Polymorphism of the chymase gene and development of retinopathy in type 2 diabetic patients.]  Pol Arch Med Wewn. 2000;  104 363-369
    PubMedGoogle Scholar
  • 144 Smith L E, Kopchick J J, Chen W, Knapp J, Kinose F, Daley D, Foley E, Smith R G, Schaeffer J M. Essential role of growth hormone in ischemia-induced retinal neovascularization.  Science. 1997;  276 1706-1709
    CrossrefPubMedGoogle Scholar
  • 145 Smith L E, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, Robinson G, Driver S, Bischoff J, Zhang B, Schaeffer J M, Senger D R. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor.  Nat Med. 1999;  5 1390-1395
    Google Scholar
  • 146 Stalmans I, Ng Y S, Rohan R, Fruttiger M, Bouche A, Yuce A, Fujisawa H, Hermans B, Shani M, Jansen S, Hicklin D, Anderson D J, Gardiner T, Hammes H P, Moons L, Dewerchin M, Collen D, Carmeliet P, D'Amore P A. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms.  J Clin Invest. 2002;  109 327-336
    CrossrefPubMedGoogle Scholar
  • 147 Stitt A, Gardiner T A, Alderson N L, Canning P, Frizzell N, Duffy N, Boyle C, Januszewski A S, Chachich M, Baynes J W, Thorpe S R, Anderson N L. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes.  Diabetes. 2002;  51 2826-2832
    CrossrefPubMedGoogle Scholar
  • 148 Stitt A W, Li Y M, Gardiner T A, Bucala R, Archer D B, Vlassara H. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats.  Am J Pathol. 1997;  150 523-531
    PubMedGoogle Scholar
  • 149 Suehiro M, Ohkubo K, Kato H, Kido Y, Anzai K, Oshima K, Ono J. Analyses of serum lipoprotein(a) and the relation to phenotypes and genotypes of apolipoprotein(a) in type 2 diabetic patients with retinopathy.  Exp Clin Endocrinol Diabetes. 2002;  110 319-324
    Article in Thieme ConnectPubMedGoogle Scholar
  • 150 Sun J, Xu Y, Zhu Y, Lu H, Deng H, Fan Y, Sun S, Zhang Y. The relationship between MTHFR gene polymorphisms, plasma homocysteine levels and diabetic retinopathy in type 2 diabetes mellitus.  Chin Med J (Engl.). 2003;  116 145-147
    PubMedGoogle Scholar
  • 151 Thomas G N, Critchley J A, Tomlinson B, Yeung V T, Lam D, Cockram C S, Chan J C. Renin-angiotensin system gene polymorphisms and retinopathy in chinese patients with type 2 diabetes.  Diabetes Care. 2003;  26 1643-1644
    PubMedGoogle Scholar
  • 152 Turner R C. The U.K. Prospective Diabetes Study. A review.  Diabetes Care. 1998;  21 Suppl 3 C35-C38
    PubMedGoogle Scholar
  • 153 Vardarli I, Baier L J, Hanson R L, Akkoyun I, Fischer C, Rohmeiss P, Basci A, Bartram C R, Van Der Woude F J, Janssen B. Gene for susceptibility to diabetic nephropathy in type 2 diabetes maps to 18q22.3 - 23.  Kidney Int. 2002;  62 2176-2183
    CrossrefPubMedGoogle Scholar
  • 154 Vijay V, Snehalatha C, Shina K, Lalitha S, Ramachandran A. Familial aggregation of diabetic kidney disease in Type 2 diabetes in south India.  Diabetes Res Clin Pract. 1999;  43 167-171
    CrossrefPubMedGoogle Scholar
  • 155 Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging.  Lab Invest. 1994;  70 138-151
    PubMedGoogle Scholar
  • 156 Wagner J, Jan Danser A H, Derkx F H, de Jong T V, Paul M, Mullins J J, Schalekamp M A, Ganten D. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: evidence for an intraocular renin-angiotensin system.  Br J Ophthalmol. 1996;  80 159-163
    CrossrefPubMedGoogle Scholar
  • 157 Wang Y, Ng M C, Lee S C, So W Y, Tong P C, Cockram C S, Critchley J A, Chan J C. Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes.  Diabetes Care. 2003;  26 2410-2415
    PubMedGoogle Scholar
  • 158 Warpeha K M, Ah-Fat F, Harding S, Patterson C C, Xu W, Hart P M, Chakravarthy U, Hughes A E. Dinucleotide repeat polymorphisms in EDN1 and NOS3 are not associated with severe diabetic retinopathy in type 1 or type 2 diabetes.  Eye. 1999;  13 (Pt 2) 174-178
    PubMedGoogle Scholar
  • 159 Warpeha K M, Xu W, Liu L, Charles I G, Patterson C C, Ah-Fat F, Harding S, Hart P M, Chakravarthy U, Hughes A E. Genotyping and functional analysis of a polymorphic (CCTTT)(n) repeat of NOS2A in diabetic retinopathy.  FASEB J. 1999 b;  13 1825-1832
    PubMedGoogle Scholar
  • 160 White W B. Ambulatory blood pressure monitoring: dippers compared with non-dippers.  Blood Press Monit. 2000;  5 Suppl 1 S17-S23
    PubMedGoogle Scholar
  • 161 Williamson J R, Chang K, Frangos M, Hasan K S, Ido Y, Kawamura T, Nyengaard J R, van den E M, Kilo C, Tilton R G. Hyperglycemic pseudohypoxia and diabetic complications.  Diabetes. 1993;  42 801-813
    CrossrefPubMedGoogle Scholar
  • 162 Wong T Y, Shankar A, Klein R, Klein B E. Retinal vessel diameters and the incidence of gross proteinuria and renal insufficiency in people with type 1 diabetes.  Diabetes. 2004;  53 179-184
    PubMedGoogle Scholar
  • 163 Xia P, Inoguchi T, Kern T S, Engerman R L, Oates P J, King G L. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia.  Diabetes. 1994;  43 1122-1129
    CrossrefPubMedGoogle Scholar
  • 164 Yamagishi S, Amano S, Inagaki Y, Okamoto T, Koda Y, Soejima M, Kimura H. Pigment epithelium-derived factor Met72Thr polymorphism in patients with diabetic microangiopathy.  Int J Clin Pharmacol Res. 2002;  22 67-71
    PubMedGoogle Scholar
  • 165 Yamagishi S, Yonekura H, Yamamoto Y, Katsuno K, Sato F, Mita I, Ooka H, Satozawa N, Kawakami T, Nomura M, Yamamoto H. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor.  J Biol Chem. 1997;  272 8723-8730
    CrossrefPubMedGoogle Scholar
  • 166 Ye X D, Laties A M, Stone R A. Peptidergic innervation of the retinal vasculature and optic nerve head.  Invest Ophthalmol Vis Sci. 1990;  31 1731-1737
    PubMedGoogle Scholar
  • 167 Yoshioka K, Yoshida T, Takakura Y, Kogure A, Umekawa T, Toda H, Yoshikawa T. No association between the MTHFR gene polymorphism and diabetic retinopathy in type 2 diabetic patients without overt nephropathy.  Diabetes Care. 2003;  26 1947-1948
    PubMedGoogle Scholar
  • 168 Yoshioka K, Yoshida T, Takakura Y, Umekawa T, Kogure A, Toda H, Yoshikawa T. Fatty acid binding protein gene 2 polymorphism is not associated with diabetic retinopathy in Japanese type 2 diabetic patients.  Horm Metab Res. 2003 b;  35 625-627
    Article in Thieme ConnectPubMedGoogle Scholar
  • 169 Young R J, McCulloch D K, Prescott R J, Clarke B F. Alcohol: another risk factor for diabetic retinopathy?.  Br Med J (Clin Res Ed). 1984;  288 1035-1037
    PubMedGoogle Scholar
  • 170 Yu H, Bowden D W, Spray B J, Rich S S, Freedman B I. Identification of human plasma kallikrein gene polymorphisms and evaluation of their role in end-stage renal disease.  Hypertension. 1998;  31 906-911
    PubMedGoogle Scholar
  • 171 Zhang J Z, Gao L, Widness M, Xi X, Kern T S. Captopril inhibits glucose accumulation in retinal cells in diabetes.  Invest Ophthalmol Vis Sci. 2003;  44 4001-4005
    CrossrefPubMedGoogle Scholar
  • 172 Zietz B, Barth N, Spiegel D, Schmitz G, Scholmerich J, Schaffler A. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 (PPARgamma2) is associated with higher levels of total cholesterol and LDL-cholesterol in male caucasian type 2 diabetes patients.  Exp Clin Endocrinol Diabetes. 2002;  110 60-66
    Article in Thieme ConnectPubMedGoogle Scholar

Prof. Dr. med. Ralf Paschke

University of Leipzig
Department of Endocrinology and Diabetes

Philipp-Rosenthal-Straße 27

04103 Leipzig

Germany

Phone: + 49 (341) 971-32 00

Fax: + 49 (341) 971-32 09

Email: Ralf.Paschke@medizin.uni-leipzig.de

      >